We recently compiled a list of the 12 AI News Investors Probably Missed. In this article, we are going to take a look at ...

Broadcom Inc. (NASDAQ:AVGO – Get Free Report) fell 0.8% during mid-day trading on Tuesday after Morgan Stanley lowered their price target on the stock from $265.00 to $246.00. Morgan Stanley currently ...

Among sell-side analysts on Wall Street, Morgan Stanley is one of the most well-known. The company’s large investment banking ...

We recently compiled a list of the 10 AI Stocks to Watch Amid the DeepSeek Buzz. In this article, we are going to take a look ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Morgan Stanley. Looking at options history for Morgan Stanley (NYSE:MS) we detected 24 trades. If we consider the ...

Morgan Stanley (MS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Financial giants have made a conspicuous bullish move on Morgan Stanley. Our analysis of options history for Morgan Stanley (NYSE:MS) revealed 8 unusual trades. Delving into the details ...

Number of Hedge Fund Holders: 44 Atlassian Corporation (NASDAQ:TEAM) creates a variety of software solutions, emphasizing AI ...

Exelixis (NASDAQ:EXEL) shares, with a market capitalization of $9.2 billion, received an optimistic update from Morgan Stanley (NYSE:MS), as the firm's analyst Sean Laaman upgraded the ...

Morgan Stanley (NYSE:MS) reaffirmed its Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT), an $11.27 billion market cap biotechnology company, with a steady price target of $200.00. The ...

Fintel reports that on January 16, 2025, Morgan Stanley downgraded their outlook for Datadog (WBAG:DDOG) from Overweight to Equal-Weight. There are 1,575 funds or institutions reporting positions ...

Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran ...